Physician profile
Brian Fuller
NPI 1780973982
$4,528.96
in general payments reported to CMS, 2019-2025
33 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $94.29 · 2021: $426 · 2022: $1,010 · 2023: $1,024 · 2024: $890 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $898.25 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $708.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $539.94 | 2022-2025 | |
| Pfizer INC. | $343.72 | 2022-2025 | |
| Encore Medical, LP | $238.77 | 2021 | |
| Abbott Laboratories | $182.77 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $163.91 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $131.62 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.32 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $129.30 | 2022 | |
| Djo, LLC | $118.19 | 2019 | |
| Glaxosmithkline, LLC. | $112.91 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Medtronic, INC. | $87.81 | 2022 | |
| Exact Sciences Corporation | $80.99 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $69.70 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $68.25 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $67.19 | 2024-2025 | Repatha, Otezla, Otezla |
| Biogen, INC. | $61.38 | 2021-2022 | |
| Eisai INC. | $60.69 | 2025 | |
| Depuy Synthes Sales INC. | $43.40 | 2020 | |
| Pacira Therapeutics, INC. | $38.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $32.60 | 2022-2025 | Airsupra |
| Xeris Pharmaceuticals, INC. | $31.18 | 2022 | |
| Astellas Pharma US INC | $23.54 | 2025 | Veozah |
| Amarin Pharma, INC. | $22.04 | 2022 | |
| Vericel Corporation | $18.00 | 2020 | |
| Esperion Therapeutics, INC. | $17.21 | 2021 | |
| Radius Health, INC. | $14.68 | 2019 | |
| Corcept Therapeutics | $14.52 | 2025 | Korlym |
| Viatris Specialty LLC | $13.77 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.08 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $12.70 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.